Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $59.77 million.

GUIDANCE:

Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $168.8 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.